We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00993629
Recruitment Status : Withdrawn (PI turned down funding.)
First Posted : October 12, 2009
Last Update Posted : October 27, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study will be an 8-week randomized, placebo-controlled clinical trial of pregnenolone administered adjunctively to treatment as usual in PTSD and depression in OEF/OIF Veterans.

Condition or disease Intervention/treatment Phase
Post-traumatic Stress Disorder Major Depressive Disorder Drug: pregnenolone Drug: placebo Phase 2

Detailed Description:
PTSD and depression are critical areas of immediate impact to Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) Veterans. Current treatments for PTSD (which frequently co-occurs with depression) remain limited, with many patients remaining symptomatic despite single or combination administration of SSRIs, mood stabilizers, antipsychotics and sedatives/hypnotics. In addition, many patients treated for depression remain symptomatic. New interventions are thus urgently needed in PTSD with co-occurring depression to ensure optimal functional outcomes for our Service members and their families.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Adjunctive Pregnenolone in PTSD and Depression in OEF/OIF Veterans
Study Start Date : January 2010
Primary Completion Date : May 2010
Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Arm 1
adjunctive pregnenolone
Drug: pregnenolone
Administered adjunctively to "treatment as usual"
Placebo Comparator: Arm 2
adjunctive placebo
Drug: placebo
adjunctive placebo

Outcome Measures

Primary Outcome Measures :
  1. Clinician Administered PTSD Scale (CAPS) [ Time Frame: 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Diagnosis of PTSD,
  • diagnosis of MDD,
  • age 18-55,
  • no change in psychotropic medication for >=4 weeks,
  • no anticipated need to to alter psychotropic medication for duration of study

Exclusion Criteria:

  • Unstable medical/neurological illness,
  • diagnosis of bipolar disorder, schizophrenia or other psychotic disorder,
  • cognitive disorder,
  • substance dependence,
  • positive urine drug screen at screening,
  • use of hormonal supplementation,
  • pregnancy/lactation,
  • female patients who are sexually active and not using acceptable non-hormonal birth control,
  • initiation/change of psychotherapy within 3 months of randomization,
  • recent/current electroconvulsive therapy,
  • regular use of opiates/barbiturates/benzodiazepines
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00993629

United States, North Carolina
VA Medical Center, Durham
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
VA Office of Research and Development
Principal Investigator: Victoria M Payne, MD MS VA Medical Center, Durham
More Information

Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00993629     History of Changes
Other Study ID Numbers: B7064-W
First Posted: October 12, 2009    Key Record Dates
Last Update Posted: October 27, 2014
Last Verified: October 2014

Keywords provided by VA Office of Research and Development:

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Pathologic Processes
Behavioral Symptoms
Mood Disorders
Mental Disorders
Trauma and Stressor Related Disorders